Resultados: 4

    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

    Clin. infect. dis; 63 (7), 2016
    The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...

    Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

    "BACKGROUND: Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies. METHODS: An American Thoracic Society-sanctioned guideline development committee selected clinical...

    The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

    Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...

    WHO treatment guidelines for drug-resistant tuberculosis, 2016 update

    In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...